IL142505A0 - EXPRESSION AND SECRETION OF icIL-1 RECEPTOR ANTAGONIST TYPE II - Google Patents
EXPRESSION AND SECRETION OF icIL-1 RECEPTOR ANTAGONIST TYPE IIInfo
- Publication number
- IL142505A0 IL142505A0 IL14250599A IL14250599A IL142505A0 IL 142505 A0 IL142505 A0 IL 142505A0 IL 14250599 A IL14250599 A IL 14250599A IL 14250599 A IL14250599 A IL 14250599A IL 142505 A0 IL142505 A0 IL 142505A0
- Authority
- IL
- Israel
- Prior art keywords
- icil
- receptor antagonist
- expression
- secretion
- antagonist type
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 230000028327 secretion Effects 0.000 title 1
- 102000000589 Interleukin-1 Human genes 0.000 abstract 2
- 108010002352 Interleukin-1 Proteins 0.000 abstract 2
- 102000002265 Human Growth Hormone Human genes 0.000 abstract 1
- 108010000521 Human Growth Hormone Proteins 0.000 abstract 1
- 239000000854 Human Growth Hormone Substances 0.000 abstract 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 abstract 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 abstract 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL14250599A IL142505A0 (en) | 1998-10-14 | 1999-10-14 | EXPRESSION AND SECRETION OF icIL-1 RECEPTOR ANTAGONIST TYPE II |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12656298A IL126562A0 (en) | 1998-10-14 | 1998-10-14 | Expression and secretion of icil-1 receptor antagonist type ii |
| IL14250599A IL142505A0 (en) | 1998-10-14 | 1999-10-14 | EXPRESSION AND SECRETION OF icIL-1 RECEPTOR ANTAGONIST TYPE II |
| PCT/IL1999/000543 WO2000022146A1 (en) | 1998-10-14 | 1999-10-14 | EXPRESSION AND SECRETION OF icIL-1 RECEPTOR ANTAGONIST TYPE II |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL142505A0 true IL142505A0 (en) | 2002-03-10 |
Family
ID=11072025
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12656298A IL126562A0 (en) | 1998-10-14 | 1998-10-14 | Expression and secretion of icil-1 receptor antagonist type ii |
| IL14250599A IL142505A0 (en) | 1998-10-14 | 1999-10-14 | EXPRESSION AND SECRETION OF icIL-1 RECEPTOR ANTAGONIST TYPE II |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12656298A IL126562A0 (en) | 1998-10-14 | 1998-10-14 | Expression and secretion of icil-1 receptor antagonist type ii |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060293230A1 (xx) |
| EP (1) | EP1121448B1 (xx) |
| JP (1) | JP2002527071A (xx) |
| AT (1) | ATE284964T1 (xx) |
| AU (1) | AU765078B2 (xx) |
| CA (1) | CA2344711A1 (xx) |
| DE (1) | DE69922679T2 (xx) |
| DK (1) | DK1121448T3 (xx) |
| ES (1) | ES2229772T3 (xx) |
| IL (2) | IL126562A0 (xx) |
| PT (1) | PT1121448E (xx) |
| SI (1) | SI1121448T1 (xx) |
| WO (1) | WO2000022146A1 (xx) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL140110A0 (en) * | 2000-12-05 | 2002-02-10 | Applied Research Systems | Improvement of homogeneity and secretion of recombinant proteins in mammalian systems |
| IL147414A0 (en) | 2001-12-31 | 2002-08-14 | Yeda Res & Dev | Ifnar2 mutants, their production and use |
| AU2004245175C1 (en) * | 2003-06-10 | 2010-03-18 | Biogen Ma Inc. | Improved secretion of neublastin |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1270662B (it) * | 1994-10-13 | 1997-05-07 | Applied Research Systems | Antagonista della interleuchina-1 |
| US6083725A (en) * | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| US5863769A (en) * | 1997-01-28 | 1999-01-26 | Smithkline Beecham Corporation | DNA encoding interleukin-1 receptor antagonist (IL-1raβ) |
-
1998
- 1998-10-14 IL IL12656298A patent/IL126562A0/xx unknown
-
1999
- 1999-10-14 EP EP99949308A patent/EP1121448B1/en not_active Expired - Lifetime
- 1999-10-14 ES ES99949308T patent/ES2229772T3/es not_active Expired - Lifetime
- 1999-10-14 IL IL14250599A patent/IL142505A0/xx unknown
- 1999-10-14 SI SI9930737T patent/SI1121448T1/xx unknown
- 1999-10-14 PT PT99949308T patent/PT1121448E/pt unknown
- 1999-10-14 AT AT99949308T patent/ATE284964T1/de not_active IP Right Cessation
- 1999-10-14 JP JP2000576036A patent/JP2002527071A/ja active Pending
- 1999-10-14 DK DK99949308T patent/DK1121448T3/da active
- 1999-10-14 AU AU62268/99A patent/AU765078B2/en not_active Ceased
- 1999-10-14 WO PCT/IL1999/000543 patent/WO2000022146A1/en active IP Right Grant
- 1999-10-14 DE DE69922679T patent/DE69922679T2/de not_active Expired - Fee Related
- 1999-10-14 CA CA002344711A patent/CA2344711A1/en not_active Abandoned
-
2005
- 2005-07-29 US US11/192,055 patent/US20060293230A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE284964T1 (de) | 2005-01-15 |
| EP1121448B1 (en) | 2004-12-15 |
| ES2229772T3 (es) | 2005-04-16 |
| DK1121448T3 (da) | 2005-01-24 |
| PT1121448E (pt) | 2005-04-29 |
| DE69922679D1 (de) | 2005-01-20 |
| DE69922679T2 (de) | 2005-05-19 |
| US20060293230A1 (en) | 2006-12-28 |
| AU765078B2 (en) | 2003-09-11 |
| CA2344711A1 (en) | 2000-04-20 |
| IL126562A0 (en) | 1999-08-17 |
| AU6226899A (en) | 2000-05-01 |
| WO2000022146A1 (en) | 2000-04-20 |
| JP2002527071A (ja) | 2002-08-27 |
| SI1121448T1 (en) | 2005-04-30 |
| EP1121448A1 (en) | 2001-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU3183389A (en) | Human relaxin formulation | |
| LU90806I2 (fr) | Ovidrelle-choriogonadotropine alfa et ses d-riv-s pharmaceutiquement acceptables | |
| IL74804A0 (en) | Human physiologically active polypeptide,its production and pharmaceutical compositions containing it | |
| NZ505324A (en) | Liquid and lyophilised KGF-2 polypeptide formulations used to accelerate soft tissue growth or regeneration | |
| IL93360A (en) | Bactericidal/permeability increasing protein or biologically active analogs thereof and pharmaceutical compositions containing them | |
| DK0859596T3 (da) | Vækstfaktorholdige gelformuleringer | |
| GEP19981274B (en) | Urinary follicle stimulating hormone, pharmaceutical composition, component of pharmaceutical composition | |
| EP0170502A3 (en) | Improvements in in vitro fertilisation | |
| EP0177342A3 (en) | Oral formulation of therapeutic proteins | |
| DK0934424T3 (da) | Fremgangsmåde til fremstilling af et rekombinant polypeptid, hvorved der adderes en inhibitor for metal-afhængige proteaser eller chymotrypsiner til cellekulturmediet | |
| Ravid et al. | 1, 25-Dihydroxyvitamin D3 inhibits selectively the mitogenic stimulation of mouse medullary thymocytes | |
| YU217890A (sh) | Postupak za dobijanje genetskih konstrukcija za ekspresiju nervnog faktora rasta u eukariotskim ćelijama | |
| IL142505A0 (en) | EXPRESSION AND SECRETION OF icIL-1 RECEPTOR ANTAGONIST TYPE II | |
| Richard et al. | High-Level Secretion of Biologically Active Recombinant Porcine Follicle-Stimulating Hormone by the Methylotrophic YeastPichia pastoris | |
| CA2191750A1 (en) | Virosome-mediated intracellular delivery of therapeutic agents | |
| WO1998037873A3 (en) | Method for reducing secretion of apolipoprotein b in animals by administering conjugated linoleic acid | |
| US7906480B2 (en) | Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy | |
| SE9403055D0 (sv) | A new human peptide antibiotic (FALL-39) and its use | |
| WO2001094414A3 (en) | THE HUMAN VOLTAGE GATED SODIUM CHANNEL β-1A SUBUNIT AND METHODS OF USE | |
| Oka et al. | The role of epidermal growth factor in normal and neoplastic growth of mouse mammary epithelial cells | |
| Vick et al. | Biological, immunological and biochemical characterization of cleaved prolactin generated by lactating mammary gland | |
| AU7655098A (en) | Somatostatin and somatostatin agonists for decreasing body weight | |
| Tsai et al. | Parathyroid hormone-related protein (1–37) induces cAMP response in human osteoblast-like cells | |
| AU6623390A (en) | Cloned genes for human dopamine d2 receptors and cell lines expressing same | |
| Brooks et al. | Phosphorylation of bovine prolactin eliminates luteotropic activity in the rat |